Standard BioTools 관리

관리 기준 확인 2/4

Standard BioTools CEO는 Adam Taich, Mar2023 에 임명되었습니다 의 임기는 1년 미만입니다. 는 € 457.50K 가치에 해당하는 회사 주식의 0.13% 직접 소유합니다. 457.50K. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 4 년입니다.

주요 정보

Adam Taich

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.1%
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	4yrs

최근 관리 업데이트

Recent updates

CEO

Adam Taich (47 yo)

less than a year

테뉴어

Mr. Adam Taich was Executive Vice President of Life Sciences Business Unit at Standard BioTools Inc. (formerly known as SomaLogic, Inc.) since August 2022 until March 28, 2023 and serves as its Interim Chi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Stephen Williams	Chief Medical Officer	15yrs	US$2.55m	0.085% € 307.0k
Adam Taich	Interim CEO	less than a year	데이터 없음	0.13% € 457.5k
Pi Zheng	Interim Chief Accounting Officer	less than a year	데이터 없음	데이터 없음
Jason Cleveland	Chief Technology Officer	3yrs	데이터 없음	데이터 없음
Nebojsa Janjic	Chief Science Officer	15yrs	데이터 없음	데이터 없음
Ruben Gutierrez	General Counsel	2yrs	데이터 없음	0.059% € 211.9k
Alison Roelke	Chief People Officer	2yrs	데이터 없음	0.0091% € 32.9k
Shane Bowen	Chief Research & Development Officer	less than a year	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

48.5yo

평균 연령

경험이 풍부한 관리: 76X0 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Richard Post	Independent Director	4.3yrs	US$202.07k	0.030% € 110.1k
Craig Mundie	Member of Advisory Board	no data	데이터 없음	데이터 없음
Eli Casdin	Independent Director	3.1yrs	US$197.57k	0.0018% € 6.6k
Jason Ryan	Independent Chairman	less than a year	데이터 없음	데이터 없음
Thomas Carey	Independent Director	less than a year	데이터 없음	데이터 없음
Troy Cox	Independent Director	2.3yrs	US$2.59m	0.042% € 150.4k
Anne Marguiles	Independent Director	4.3yrs	US$204.70k	0.012% € 44.9k
Peter Ganz	Member of Medical Advisory Board	4yrs	데이터 없음	데이터 없음
Rosalind Raine	Member of Medical Advisory Board	4yrs	데이터 없음	데이터 없음
Marc Feldmann	Member of Medical Advisory Board	4yrs	데이터 없음	데이터 없음
Michael Blum	Member of Medical Advisory Board	4yrs	데이터 없음	데이터 없음
John Tooke	Member of Medical Advisory Board	4yrs	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: 76X0 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.

Standard BioTools 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

Somalogic, Inc. Announces Chief Financial Officer Changes

Less than half of directors are independent

High number of new and inexperienced directors

SomaLogic, Inc. Announces the Appointment of Troy Cox as Executive Chairman of the Board of Directors

Melody Harris to Leave SomaLogic, Inc. as President and Chief Operating Officer, Effective August 31, 2022

Recent updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Madryn Asset Management, LP Issues Presentation to SomaLogic Shareholders

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

Somalogic, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.18 loss in 3Q 2022)

Somalogic Announces New Somascan® 11K Platform

SomaLogic, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

SomaLogic, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Somalogic, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.022 loss in 1Q 2022)

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

Less than half of directors are independent

Full year 2022 earnings released: US$0.59 loss per share (vs US$0.64 loss in FY 2021)

SomaLogic, Inc. Provides Revenue Guidance for Full Year 2022

SomaLogic, Inc. Announces the Full-Scale Global Launch of the SomaLogic Certified Site Program

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.30 loss in 3Q 2021)

High number of new and inexperienced directors

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2022

SomaLogic, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SomaLogic, Inc. Announces the Appointment of Troy Cox as Executive Chairman of the Board of Directors

Melody Harris to Leave SomaLogic, Inc. as President and Chief Operating Officer, Effective August 31, 2022

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 2Q 2021)

SomaLogic Provides Revenue Guidance for the Full Year 2022

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SomaLogic, Inc. Announces Resignation of Stephen Quake from the Board of Directors, Effective July 17, 2022

First quarter 2022 earnings released: US$0.022 loss per share (vs US$0.13 loss in 1Q 2021)

SomaLogic, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

SomaLogic, Inc., Annual General Meeting, Jun 06, 2022

SomaLogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings released: US$0.64 loss per share (vs US$0.81 loss in FY 2020)

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

SomaLogic, Inc. to Report Q4, 2021 Results on Mar 29, 2022

Now 23% undervalued after recent price drop

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

SomaLogic Announces That the Company Will Begin Assaying Samples from the Multi-Ethnic Study of Atherosclerosis (Mesa) Study Beginning in the First Quarter of 2022

Oncohost Ltd. Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy

SomaLogic, Inc. Revises Revenue Guidance for the Year Ended December 31, 2021

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.55 loss per share

Director recently bought €136k worth of stock

No independent directors

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령